Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Abbott Laboratories (ABT), Eli Lilly & Co. (LLY) And Why Diabetes Isn’t Good for Health, But It Can Be for Your Portfolio

Page 1 of 2

3 High-Yield Pharma Stocks With Major CatalystsWhen I was six years old, something happened to me that I have never forgotten and will probably always live with. I couldn’t eat without informing my parents exactly what I was eating, and had to have shots of insulin multiple times a day. Diabetes had busted in and turned my life around in a very short period of time.

Within just a few years, I became well aware of how much money certain pharmaceutical companies made due to this disease. My family had seen the devastating effects of this disease first hand — my dad was an M.D. and my mom an RN.  Many companies generate insane amounts of money from this disease each year, but how are their stocks performing and what value do they provide for investors?

The first change I became well aware of was the need to check blood glucose levels multiple times a day. One of the major test-strip manufacturers is Abbott Laboratories (NYSE:ABT), which spun off AbbVie in January this year. This spin off virtually cut the company in half, leaving the test-strip manufacturing to Abbott.

Since spinning off, Abbott Laboratories (NYSE:ABT)’s stock is up nearly 18%, and the company recently announced its first-quarter earnings. Worldwide sales increased 3.5%, driven largely by its sales in diagnostics, nutrition, and international growth which increased 6.4%, 9.0%, and 14.8%, respectively.

Diabetes care provided $316 million in revenue to the company, which is roughly 5.9% of the company’s total sales in the first quarter. Medical devices account for 24.7% of Abbott Laboratories (NYSE:ABT)’s overall sales, 23.8% of which is derived from diabetic care. The first quarter adjusted earnings per share (EPS) were $0.42, at the high end of the previous guidance. On Feb. 15, Abbott announced its 357th quarterly dividend, an amount of $0.14 per share.

Humalog is a fast acting insulin used by most type 1 diabetics. Eli Lilly & Co. (NYSE:LLY) distributes this insulin, and it was the second largest revenue generator for the company in the previous quarter. Humalog saw a 7% increase from the same-quarter last year, and accounted for 11.3% of Lilly’s total revenue. Over $632 million was spent on Humalog in Q1, but the company’s earnings were even more impressive. EPS rose 56% to $1.42, up from $0.91 in 2012.

Eli Lilly & Co. (NYSE:LLY)’s revenue remained flat as a patent expiration took place on Zyprexa. Growth in key products offset this loss, and the company expects growth throughout the year. In fact, they expect EPS to rise between 12%-16% when compared to 2012. Shareholders have enjoyed a 14% increase in the stock price so far this year.

Let’s look at why diabetes could play a major role in Johnson & Johnson (NYSE:JNJ) over time. It may not currently play as huge of a role as it does in a company like Lilly, but with time, it likely will. The incidence of Type 2 diabetes is strongly correlated to the rise in obesity, and according to the CDC (Centers for Disease Control and Prevention), 35.7% of people in the world are now obese.

Invokana, otherwise referred to as Canagliflozin, gave Johnson & Johnson (NYSE:JNJ) a major boost recently as it was granted FDA approval. According to GBI research, the type 2 diabetes drug market is expected to rise from $26 billion in 2011 to $50 billion in 2021.

Page 1 of 2
Loading Comments...